Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Theravance Biopharma (TBPH) EBIT: 2013-2025

Historic EBIT for Theravance Biopharma (TBPH) over the last 13 years, with Sep 2025 value amounting to -$6.5 million.

  • Theravance Biopharma's EBIT rose 40.44% to -$6.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$32.8 million, marking a year-over-year increase of 25.40%. This contributed to the annual value of -$46.9 million for FY2024, which is 16.21% up from last year.
  • Per Theravance Biopharma's latest filing, its EBIT stood at -$6.5 million for Q3 2025, which was down 136.88% from -$2.7 million recorded in Q2 2025.
  • Theravance Biopharma's 5-year EBIT high stood at -$2.7 million for Q2 2025, and its period low was -$83.9 million during Q1 2021.
  • In the last 3 years, Theravance Biopharma's EBIT had a median value of -$10.8 million in 2024 and averaged -$11.5 million.
  • Per our database at Business Quant, Theravance Biopharma's EBIT surged by 82.95% in 2022 and then slumped by 47.44% in 2024.
  • Over the past 5 years, Theravance Biopharma's EBIT (Quarterly) stood at -$56.2 million in 2021, then soared by 68.96% to -$17.4 million in 2022, then spiked by 64.20% to -$6.2 million in 2023, then plummeted by 47.44% to -$9.2 million in 2024, then surged by 40.44% to -$6.5 million in 2025.
  • Its EBIT was -$6.5 million in Q3 2025, compared to -$2.7 million in Q2 2025 and -$14.4 million in Q1 2025.